JPH10109941A - Antiinflammable agent - Google Patents
Antiinflammable agentInfo
- Publication number
- JPH10109941A JPH10109941A JP8299196A JP29919696A JPH10109941A JP H10109941 A JPH10109941 A JP H10109941A JP 8299196 A JP8299196 A JP 8299196A JP 29919696 A JP29919696 A JP 29919696A JP H10109941 A JPH10109941 A JP H10109941A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- extract
- magnolia obovata
- antiinflammable
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は抗炎症剤に関する。This invention relates to anti-inflammatory agents.
【0002】[0002]
【従来の技術】抗炎症剤の原料として使用できる物質と
しては種々の物質が知られているが、合成品は、長期間
人間の肌に適応した場合の安全性の保証がなく、使用が
制限されつつある。一方、天然物ではその作用が弱いも
のが多い。しかし人の肌に対する安全性の面から天然物
で、多年、人が食したりして、安全性の面で保証されて
おり、更に皮膚に対する他の効果も合わせてもつ物質が
望まれていた。厚朴はホウノキ(Magnolia o
bovata)カラホウ(Magnolia offi
cinalis)等の樹皮及び根皮の乾燥したものをい
い、健胃、消化、整腸、収斂、去痰、利尿剤として、胸
腹部の膨満、腹痛、喘咳などに利用されている。ホーノ
キオール、マグノロールは厚朴に含有されている。これ
らは特開平4−82814号、特開平4−82830
号、特開平4−82816号公報に美白化粧品、ニキビ
用皮膚外用剤、スクラブ洗顔料などに応用されている。2. Description of the Related Art Although various substances are known as substances that can be used as a raw material of an anti-inflammatory agent, there is no guarantee of safety when applied to human skin for a long time, and the use of synthetic products is limited. Is being done. On the other hand, many natural products have a weak effect. However, there is a need for a substance that is a natural product that is safe from human consumption for many years, and that also has other effects on skin, in terms of safety for human skin. The magnolia is Magnolia o
bovata) Karahou (Magnolia offi)
Cinalis) and its dried bark and root bark. It is used as a stomachic, digestive, intestinal, astringent, expectorant and diuretic for bloating of the thorax and abdomen, abdominal pain, asthma and the like. Hornokiol and magnolol are contained in the lavender. These are disclosed in JP-A-4-82814 and JP-A-4-82830.
No. 4,828,816, which are applied to whitening cosmetics, external preparations for acne, facial scrubs and the like.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、皮膚
に適用して安全であると共に、抗炎症作用が大きく且つ
肌荒れなどに有効な成分を含んだ抗炎症剤を提供するこ
とである。SUMMARY OF THE INVENTION An object of the present invention is to provide an anti-inflammatory agent which is safe when applied to the skin, has a large anti-inflammatory effect, and contains an effective ingredient for rough skin.
【0004】[0004]
【課題を解決する手段】本発明者らは、前記の課題を解
決するため、すでに多年にわたって食用に供され、人体
に対する安全性が確認されている植物をスクリーニング
して調べ、抗炎症剤として利用価値のあるものを検討し
た。その結果、非常に抗炎症剤原料として、或いは医薬
部外品としての有効性を有することを見出した。Means for Solving the Problems In order to solve the above-mentioned problems, the present inventors have screened and examined plants which have been edible for many years and whose safety to the human body has been confirmed, and utilized them as anti-inflammatory agents. We considered something worthwhile. As a result, they have found that they are very effective as raw materials for anti-inflammatory agents or as quasi-drugs.
【0005】すなわち、本発明は、厚朴の溶媒抽出物或
いは又はホウノキオール或いは又はマグノロールを含む
抗炎症剤である。ホウノキオール或いは又はマグノロー
ルは厚朴に含まれ、厚朴は漢方として広く飲用され安全
性も確認されている。[0005] That is, the present invention is an anti-inflammatory agent containing a solvent extract of magnolia or or honokiol or or magnolol. Honokiol or magnolol is contained in magnolia, and magnolia is widely consumed as a Chinese medicine and its safety has been confirmed.
【0006】この利用方法としては、水或いは親水性有
機溶媒例えば、エタノール、メタノール、アセトン等で
抽出する。しかしながら、抗炎症剤原料の抽出であるか
ら、水或いはエタノール或いはこれの混合溶媒での抽出
が好ましいのは当然である。また、場合によっては、グ
リセリン、1,3ブチレングリコール、プロピレングリ
コール等の多価アルコール又は多価アルコールと水の混
液も抽出に利用できる。またさらに凍結乾燥して粉体と
して利用することも利用方法によっては有効である。[0006] As a method of use, extraction is carried out with water or a hydrophilic organic solvent such as ethanol, methanol, acetone or the like. However, it is a matter of course that extraction with water, ethanol or a mixed solvent thereof is preferable because it is an extraction of the anti-inflammatory agent raw material. In some cases, a polyhydric alcohol such as glycerin, 1,3-butylene glycol, propylene glycol, or a mixture of polyhydric alcohol and water can also be used for extraction. It is also effective to freeze-dry and use as a powder depending on the method of use.
【0007】この物質を他の抗炎症剤原料例えばスクワ
ラン、ホホバ油等の液状油、ミツロウ、セチルアルコー
ル等の固体油、各種の活性剤、グリセリン、1,3ブチ
レングリコール等の保湿剤や各種薬剤等を添加してさま
ざまな剤形の抗炎症剤を調整することができる。例えば
ローション、クリーム、乳液、パック等で目的に応じて
利用形態を考えればよい。This substance is used as a raw material for other anti-inflammatory agents such as liquid oils such as squalane and jojoba oil, solid oils such as beeswax and cetyl alcohol, various activators, humectants such as glycerin and 1,3-butylene glycol, and various chemicals. And the like can be added to adjust various forms of anti-inflammatory agents. For example, a use form may be considered depending on the purpose, such as a lotion, a cream, an emulsion, a pack, and the like.
【0008】[0008]
【実施例】以下に実際の利用方法である実施例を記載す
るが、本発明はこの実施例によって何ら限定されるもの
ではない。本発明で使用したの抽出物の製造例を次に示
す。EXAMPLES An example of an actual use method will be described below, but the present invention is not limited to this example. Production examples of the extract used in the present invention are shown below.
【0009】製造例 厚朴(乾燥品)を20gにエタノール300mlを加え
て時々攪拌しつつ5日間放置した。これを濾過後、エバ
ポレートした後、凍結乾燥した。Production Example 20 g of dried mackerel (dry product) was added to 300 ml of ethanol, and left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.
【0010】 実施例−1 ローション オリーブ油 0.5 製造例の抽出物 0.5 ポリオキシエチレン(20E.O)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O)硬化ヒマシ油 2.0 エタノール 10.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 精製水 80.0Example-1 Lotion Olive Oil 0.5 Extract of Preparation Example 0.5 Polyoxyethylene (20EO) Sorbitan Monostearate 2.0 Polyoxyethylene (60EO) Hardened Castor Oil 2.0 Ethanol 10.0 1.0% aqueous solution of sodium hyaluronate 5.0 Purified water 80.0
【0011】 実施例−2 クリーム A スクワラン 20.0 オリーブ油 2.0 ミンク油 1.0 ホホバ油 5.0 ミツロウ 5.0 セトステアリルアルコール 2.0 グリセリンモノステアレート 1.0 ソルビタンモノステアレート 2.0 ホウノキオール 1.0 B 精製水 47.9 ポリオキシエチレン(20E.O)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O)硬化ヒマシ油 1.0 グリセリン 5.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 パラオキシ安息香酸メチル 0.1 AとBをそれぞれ計量し、70℃まで加温し、BにAを
攪拌しつつ徐々に加えたのち、ゆっくり攪拌しつつ30
℃まで冷却した。Example-2 Cream A Squalane 20.0 Olive Oil 2.0 Mink Oil 1.0 Jojoba Oil 5.0 Beeswax 5.0 Cetostearyl Alcohol 2.0 Glycerin Monostearate 1.0 Sorbitan Monostearate 2. 0 honokiol 1.0 B purified water 47.9 polyoxyethylene (20EO) sorbitan monostearate 2.0 polyoxyethylene (60EO) hydrogenated castor oil 1.0 glycerin 5.0 1.0% hyaluronic Aqueous sodium acid solution 5.0 Methyl paraoxybenzoate 0.1 A and B were each weighed, heated to 70 ° C., and A was gradually added to B with stirring, and then slowly stirred for 30 minutes.
Cooled to ° C.
【0012】実施例3 実施例1の製造例の抽出物をマグノロールに変えて作成
したものExample 3 The extract prepared in Example 1 was prepared by changing the extract to magnolol.
【0013】プロスタグランジンE2(以下PGE2と
略す)生成抑制試験方法 正常ヒト皮膚繊維芽細胞を48ウェルセルプレートに分
植し、コンフェルントになるまで培養した。培地は、牛
胎児血清を10%含むEagle’sMEM培地を用
い、37℃、5%CO2で培養した。培地を牛アルブミ
ン0.1%含むEagle’sMEM培地に交換し、さ
らに一晩培養した。培養液を除去後、試験品を含む牛ア
ルブミン0.1%含むEagle’sMEM培地を1ウ
ェルにつき0.8ml加え、インターロイキン1−βを
5ng/mlになるように添加し、さらに一晩培養し
た。培養液中に遊離されたプロスタグランジンE2は酵
素免疫測定法(EIA)にて測定した。また、試験品の
細胞に対する影響を知るためにパラニトロフェノールリ
ン酸にて酸性フォスタファーゼ活性を測定した。Prostaglandin E2 (hereinafter abbreviated as PGE2) production inhibition test method Normal human dermal fibroblasts were seeded in a 48-well cell plate and cultured until they became confluent. Eagle's MEM medium containing 10% fetal calf serum was used as the medium, and the cells were cultured at 37 ° C. and 5% CO 2. The medium was replaced with Eagle's MEM medium containing 0.1% bovine albumin, and the cells were further cultured overnight. After removing the culture solution, 0.8 ml of Eagle's MEM medium containing 0.1% of bovine albumin containing the test product was added to each well, and interleukin 1-β was added to 5 ng / ml, followed by further culturing overnight. did. Prostaglandin E2 released into the culture solution was measured by enzyme immunoassay (EIA). In addition, the acid phosphatase activity was measured with paranitrophenol phosphate to determine the effect of the test article on cells.
【0014】試験品濃度 製造例は、エタノールに1mg/mlに溶解後、牛アル
ブミン0.1%含むEagle’sMEM培地にて12
5,250,500,1000ng/mlに希釈して用
いた。また、陽性対象としてデキサメタソン10nM、
サリチル酸(SA)1nMも同時に検討した。Test Article Concentration In a production example, after dissolving at 1 mg / ml in ethanol, 12% in Eagle's MEM medium containing 0.1% of bovine albumin.
It was used after being diluted to 5,250,500,1000 ng / ml. Dexamethasone 10 nM as a positive control,
Salicylic acid (SA) 1 nM was also studied at the same time.
【0015】試験結果を表1に示す。Table 1 shows the test results.
【表1】 相対値は、 (検体のPGE2産生量÷コントロールのPGE2産生
量)÷(検体の酸性フォスタファーゼ活性値÷コントロ
ール酸性フォスタファーゼ活性値)[Table 1] The relative value is (the amount of PGE2 produced by the sample ÷ the amount of PGE2 produced by the control) ÷ (the acid phosphatase activity of the sample ÷ the control acid phosphatase activity)
【0016】使用テスト 女性6名の顔面を左右に分け、一方を実施例、もう一方
を比較例として毎日、1回以上使用してもらって、3月
後、アンケートした。なお、比較例は実施例より製造例
の抽出物、或いはホウノキオール、マグノロールを水に
かえたものである。(比較例1,2) なお、12名を
2班にわけ、下記の試料を使って実験した。 判定基準は以下のようでアンケートの結果をまとめたの
が以下の表である。 実施例の方が非常によい 3 実施例の方がかなりよい 2 実施例の方がややよい 1 差がない 0 比較例の方がややよい −1 比較例の方がかなりよい −2 比較例の方が非常によい −3Usage Test The faces of six women were divided into left and right, one of which was used as an example and the other was used as a comparative example. In the comparative example, the extract of the production example, or honokiol and magnolol were replaced with water from the examples. (Comparative Examples 1 and 2) Twelve people were divided into two groups, and experiments were performed using the following samples. The following table summarizes the results of the questionnaire with the following criteria. Example is very good 3 Example is considerably better 2 Example is slightly better 1 No difference 0 Comparative example is slightly better -1 Comparative example is much better -2 Comparative example Is much better -3
【0017】結果を次の表に示す。 The results are shown in the following table.
【0018】[0018]
【効果】厚朴溶媒抽出物、あるいはホーノキオール、マ
グノロールを含む抗炎症剤は、プロスタグランジンE2
生成抑制作用があり、抗炎症剤として非常に有効であ
る。[Effect] Anti-inflammatory agents containing honey solvent extract or honokiol and magnolol are prostaglandin E2
It has a production inhibiting action and is very effective as an anti-inflammatory agent.
Claims (2)
炎症剤2. An anti-inflammatory agent comprising honokiol and magnolol
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8299196A JPH10109941A (en) | 1996-10-03 | 1996-10-03 | Antiinflammable agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8299196A JPH10109941A (en) | 1996-10-03 | 1996-10-03 | Antiinflammable agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10109941A true JPH10109941A (en) | 1998-04-28 |
Family
ID=17869392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8299196A Pending JPH10109941A (en) | 1996-10-03 | 1996-10-03 | Antiinflammable agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10109941A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005194245A (en) * | 2004-01-09 | 2005-07-21 | Ichimaru Pharcos Co Ltd | NF-kappaB ACTIVATION INHIBITOR |
JP2006328048A (en) * | 2005-04-28 | 2006-12-07 | Kanebo Cosmetics Inc | Skin cosmetic |
JP2021001227A (en) * | 2020-10-06 | 2021-01-07 | 小林製薬株式会社 | External composition |
-
1996
- 1996-10-03 JP JP8299196A patent/JPH10109941A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005194245A (en) * | 2004-01-09 | 2005-07-21 | Ichimaru Pharcos Co Ltd | NF-kappaB ACTIVATION INHIBITOR |
JP2006328048A (en) * | 2005-04-28 | 2006-12-07 | Kanebo Cosmetics Inc | Skin cosmetic |
JP2021001227A (en) * | 2020-10-06 | 2021-01-07 | 小林製薬株式会社 | External composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH1072336A (en) | Collagen gel contraction accelerator | |
JP4915714B2 (en) | Collagen gel contraction promoter | |
JP2000191498A (en) | Collagen production facilitative agent and preparation for external use for skin | |
PT759740E (en) | USING LAMINARINE AND OLIGOSACARIDES DERIVED FROM LAMINARIN IN COSMETOLOGY FOR THE MANUFACTURE OF A DRUG TREATMENT MEDICINE | |
JP2007262012A (en) | Hyaluronic acid production promoter, skin external preparation containing the hyaluronic acid production promoter, cosmetic, quasi drug, chapped skin ameliorating agent, and wrinkle ameliorating agent | |
JPH07277939A (en) | Skin external preparation | |
JPH1025238A (en) | Preparation for external use for skin | |
JP7090886B2 (en) | Hydrolyzate of watery rose apple extract and method for producing the hydrolyzate and use of the hydrolyzate | |
KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
CN107970278B (en) | Hydrolysate of water extract of wax apple, preparation method and application thereof | |
TWI635873B (en) | Hydrolysate of water extract ofsyzygium samarangense, and the preparation process and uses thereof | |
JP3278138B2 (en) | External preparation for skin | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
JPH10114670A (en) | Composition suitable for external use | |
JPH10109941A (en) | Antiinflammable agent | |
JPH07126143A (en) | Cosmetic | |
JPH10109924A (en) | Beautifying and whitening cosmetic | |
JPH0687731A (en) | Cosmetic | |
TWI648054B (en) | Hydrolysate of water extract of Asparagus officinalis, preparation method and use thereof | |
JPH08217688A (en) | Hyaluronidase inhibitor | |
JP3792745B2 (en) | Tyrosinase inhibitor | |
JP2001114637A (en) | Hyaluronic acid production promoting agent and skin lotion containing the agent | |
JPH0867616A (en) | Cosmetic | |
JPH07118135A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070206 |